Qiyue Hu

This inventor holds 21 USPTO granted patents and 13 published patent applications, plus 3 CIPO patents and 8 EPO patents, primarily in Antibody Therapeutics. Top assignees: Jiangsu Hengrui Medicine Company Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd., Suzhou Suncadia Biopharmaceuticals Co., Ltd.. Active years: 2017-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Qiyue Hu. Retrieved from https://idiyas.com/inventor/qiyue-hu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 21 (Patent Applications = 13)

% Patents Active = 81.0

CIPO Patents = 3 (Patent Applications = 11)

EPO Patents = 8 (Patent Applications = 27)

Average Co-Inventor Count = 6.1

ph-index = 3

Forward Citations = 26(Granted Patents)

Company Filing History:

21 out of 159

Jiangsu Hengrui Medicine Company Ltd.

patents

18 out of 100

Shanghai Hengrui Pharmaceutical Co., Ltd.

patents

2 out of 8

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

patents

4. 1 out of 10

Shanghai Hengrui Pharmaceutical

patents

5. 1 out of 5

Shanghai Shengdi Pharmaceutical Co., Ltd.

patents

where one patent can have more than one assignee

Years Active: 2017-2026

Loading Chart...

Areas of Expertise:

Human Interleukin-2

Anti-Aβ Antibodies

IL-5 Antibody

LAG-3 Antibody

PD-L1 Antibody

Interleukin 15

Anti-CD40 Antibody

TIGIT Antibody

PCSK9 Antibody

Fused Tricyclic Heterocycles

Pyrazolo-Heteroaryl Derivatives

Aminopyridazinone Compounds

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12723067 - HUMAN INTERLEUKIN-2 VARIANT OR DERIVATIVE THEREOF (2026-09-01),

2. 12325741 - Anti-Aβ antibodies and antigen-binding fragments thereof (2025-06-10),

3. 12258394 - IL-5 antibody, antigen binding fragment thereof, and medical application therefor (2025-03-25),

4. 11981733 - LAG-3 antibody, antigen-binding fragment thereof, and pharmaceutical application thereof (2024-05-14),

5. 11780923 - PD-L1 antibody, antigen-binding fragment thereof and medical application thereof (2023-10-10),

6. 11717559 - Interleukin 15 protein complex and use thereof (2023-08-08),

7. 11535633 - Fused tricyclic heterocycle compounds and therapeutic uses thereof (2022-12-27),

8. 11525005 - Anti-CD40 antibody, antigen binding fragment thereof and medical use thereof (2022-12-13),

9. 11512129 - TIGIT antibody, antigen-binding fragment thereof, and medical use thereof (2022-11-29),

10. 11365247 - IL-5 antibody, antigen binding fragment thereof, and medical application therefor (2022-06-21),

11. 11359021 - PD-L1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof (2022-06-14),

12. 11155617 - LAG-3 antibody, antigen-binding fragment thereof, and pharmaceutical application thereof (2021-10-26),

13. 11117898 - Pyrazolo-heteroaryl derivative, preparation method and medical use thereof (2021-09-14),

14. 10905743 - Interleukin 15 protein complex (2021-02-02),

15. 10815304 - PD-L1 antibody, antigen-binding fragment thereof and medical application thereof (2020-10-27),

Title: Innovations of Qiyue Hu: Advancements in Antibody Research

Introduction: Qiyue Hu, based in Shanghai, China, is a prominent inventor in the medical field with a remarkable contribution of 19 patents. His work primarily revolves around antibodies and their pharmaceutical applications, showcasing his dedication to advancing medical science and treatment options.

Latest Patents: Among Qiyue's latest patents are groundbreaking inventions such as the IL-5 antibody and its antigen-binding fragment. This invention includes a comprehensive range of applications, such as a pharmaceutical composition featuring the IL-5 antibody, alongside the importance of its application as a drug. Another significant patent includes the LAG-3 antibody and its antigen-binding fragment. This invention highlights the development of a chimeric antibody, humanized antibodies, and a pharmaceutical composition aimed at treating diseases involving immune cells, particularly as an antineoplastic drug.

Career Highlights: Qiyue Hu's professional journey includes crucial roles in notable companies like Jiangsu Hengrui Medicine Company Ltd. and Shanghai Hengrui Pharmaceutical Co., Ltd. His work in these organizations has significantly contributed to the advancement of therapeutic antibodies in the medical field.

Collaborations: Throughout his career, Qiyue has had impactful collaborations with colleagues such as Weikang Tao and Piaoyang Sun. Their combined expertise has likely fueled innovation and invention, driving forward the potential applications of their research.

Conclusion: Qiyue Hu exemplifies the spirit of innovation through his patents that focus on the vital area of antibody research. By merging scientific inquiry with practical applications, he significantly enhances the landscape of medical treatment, showcasing the profound impact inventors can have on healthcare.

Profile summary based on public USPTO records.